查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596200

肾臟生物标记市场：按标记类型、检测平台类型、应用和最终用户 - 2025-2030 年全球预测

Renal Biomarkers Market by Marker Type (Blood Urea Nitrogen, Creatinine, Cystatin C), Assay Platform Type (Enzymatic Assay, Enzyme-Linked Immunosorbent Assay (ELISA), Turbidimetric Immunoassay), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肾臟生物标记市场价值为13.3亿美元，预计到2024年将达到14.3亿美元，复合年增长率为7.72%，到2030年将达到22.4亿美元。

肾臟生物标记是检测肾功能和肾臟损伤的重要指标，为肾臟疾病的早期诊断和监测提供了一种非侵入性方法。由于慢性肾臟病(CKD) 和急性肾损伤 (AKI) 的盛行率不断增加，对肾臟生物标记的需求产生了，早期检测可以显着改变疾病进展和患者预后。这些生物标记在临床诊断、药物开发和个人化治疗计划中具有广泛的应用。最终用途广泛，包括医院、诊断实验室和研究机构。影响肾臟生物标记市场的主要成长要素包括 CKD 和心血管疾病的增加、生物标记研究的技术进步以及医疗保健支出的增加。对个人化医疗的快速增长的需求以及基于人工智慧的分析在生物标誌物发现中的整合凸显了巨大的商机。公司可以透过投资持续研发、策略联盟和扩大产品系列，利用这些进步并有效捕捉市场潜力。

主要市场统计
基准年[2023] 13.3亿美元
预测年份 [2024] 14.3亿美元
预测年份 [2030] 22.4亿美元
复合年增长率（%） 7.72%

然而，市场成长受到多种限制和挑战的限制，包括生物标记发现和检验的高成本、监管障碍以及缺乏标准化程序。此外，新兴国家有限的意识和基础设施可能会带来额外的挑战。创新和研究的最佳领域包括开发具有更高特异性和敏感性的新型生物标誌物，探索用于综合诊断的多生物标记组合，以及增强资料分析和预测能力的生物资讯学和人工智慧，例如技术投资。研究人员、生物製药公司和监管机构需要共同努力，克服市场障碍并促进创新。市场竞争激烈，发展迅速，需要不断适应新的科学考量和技术开拓。透过领先并应对成本和效率挑战，公司可以推动成长并保持市场竞争力。

市场动态：快速发展的肾臟生物标记市场的关键市场洞察

供需的动态交互作用正在改变肾臟生物标记市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 人群中肾功能损害的盛行率不断增加
    • 加强意识提升
    • 个人化药物和标靶治疗的发展趋势
  • 市场限制因素
    • 与肾臟生物标记相关的高成本
  • 市场机会
    • 积极研究引入新的肾臟生物标记
    • 肾臟手术新技术进展
  • 市场挑战
    • 对生物标记失败的担忧

波特五力：驾驭肾臟生物标记市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肾臟生物标记市场的外部影响

外部宏观环境因素在塑造肾臟生物标记市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解肾臟生物标记市场的竞争格局

肾臟生物标记市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵肾臟生物标记市场供应商的绩效评估

FPNV定位矩阵是评估肾臟生物标记市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製肾臟生物标记市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对肾臟生物标记市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人群中肾臟病盛行率上升
      • 加强提高人们对肾臟疾病和肾臟生物标记的认识
      • 个人化药物和标靶治疗的发展趋势
    • 抑制因素
      • 与肾臟生物标记相关的高成本
    • 机会
      • 大力研究引入新的肾臟生物标记
      • 肾臟手术新技术进展
    • 任务
      • 对生物标记失败的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章按标记类型分類的肾臟生物标记市场

  • 血中尿素氮
  • 肌酸酐
  • Cystatin C
  • 嗜中性白血球明胶酶相关脂质运载蛋白

第 7 章按检测平台类型分類的肾臟生物标记市场

  • 酵素测定
  • 酵素免疫分析法测定法 (ELISA)
  • 免疫检测

第八章肾臟生物标记市场：依应用分类

  • 疾病进展的诊断和监测
  • 调查

第 9 章 肾臟生物标记市场：依最终用户分类

  • 诊断实验室
  • 医院

第10章美洲肾臟生物标记市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区肾臟生物标记市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的肾臟生物标记市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • BioPorto Diagnostics A/S
  • Cipla Limited
  • Danaher Corporation
  • DiaSorin SpA
  • Eli Lilly and Co
  • Enzo Biochem, Inc.
  • Eurofins Viracor Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Novartis AG
  • Novatein Biosciences Inc.
  • PerkinElmer Inc.
  • Randox Laboratories Ltd.
  • Renalytix AI PLC
  • Sanofi-Aventis, LLC.
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • SphingoTec GmbH
  • Thermo Fisher Scientific Inc.
Product Code: MRR-521BAA36EA84

The Renal Biomarkers Market was valued at USD 1.33 billion in 2023, expected to reach USD 1.43 billion in 2024, and is projected to grow at a CAGR of 7.72%, to USD 2.24 billion by 2030.

Renal biomarkers are critical indicators used to detect kidney function and damage, offering a non-invasive method for early diagnosis and monitoring of renal diseases. The necessity for renal biomarkers arises from the growing prevalence of chronic kidney diseases (CKD) and acute kidney injuries (AKI), where early detection can significantly alter disease progression and patient outcomes. These biomarkers are applied extensively across clinical diagnostics, drug development, and personalizing treatment plans. The end-use spans across hospitals, diagnostic laboratories, and research institutions. Key growth factors influencing the renal biomarker market include the rising incidences of CKD and cardiovascular diseases, technological advancements in biomarker research, and increased healthcare expenditure. The burgeoning demand for personalized medicine and the integration of AI-based analytics in biomarker discovery highlight substantial opportunities. Companies can leverage these advancements by investing in continuous R&D, strategic collaborations, and expanding their product portfolios to capture the market potential effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 1.33 billion
Estimated Year [2024] USD 1.43 billion
Forecast Year [2030] USD 2.24 billion
CAGR (%) 7.72%

However, market growth is restricted by several limitations and challenging factors such as the high costs of biomarker discovery and validation, regulatory hurdles, and the lack of standardized procedures. Furthermore, limited awareness and infrastructure in emerging economies may pose additional challenges. The best areas for innovation and research include developing novel biomarkers with higher specificity and sensitivity, exploring multi-biomarker panels for comprehensive diagnosis, and investing in bioinformatics and AI technologies to enhance data analysis and prediction capabilities. There's a need for collaborative efforts between researchers, biopharma companies, and regulatory bodies to overcome market barriers and expedite innovation. The nature of the market is highly competitive, characterized by rapid advancements, and requires continuous adaptation to new scientific insights and technological developments. By staying ahead in innovation and addressing the challenges of cost and efficiency, businesses can drive growth and maintain a competitive edge in the renal biomarkers market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Renal Biomarkers Market

The Renal Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of renal disorders among population
    • Growing initiatives to create awareness on renal diseases and renal biomarkers
    • Trend towards developing personalized medicines and targeted therapies
  • Market Restraints
    • High costs associated with renal biomarkers
  • Market Opportunities
    • Robust research activities to introduce new renal biomarkers
    • Emerging technological advancements in renal surgeries
  • Market Challenges
    • Concerns over failure of biomarkers

Porter's Five Forces: A Strategic Tool for Navigating the Renal Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Renal Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Renal Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Renal Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Renal Biomarkers Market

A detailed market share analysis in the Renal Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Renal Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Renal Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Renal Biomarkers Market

A strategic analysis of the Renal Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Renal Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Bio-Rad Laboratories, Inc., bioMerieux SA, BioPorto Diagnostics A/S, Cipla Limited, Danaher Corporation, DiaSorin S.p.A., Eli Lilly and Co, Enzo Biochem, Inc., Eurofins Viracor Inc., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Novartis AG, Novatein Biosciences Inc., PerkinElmer Inc., Randox Laboratories Ltd., Renalytix AI PLC, Sanofi-Aventis, LLC., Sekisui Diagnostics, LLC, Siemens Healthineers AG, SphingoTec GmbH, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Renal Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Marker Type, market is studied across Blood Urea Nitrogen, Creatinine, Cystatin C, and Neutrophil Gelatinase-Associated Lipocalin.
  • Based on Assay Platform Type, market is studied across Enzymatic Assay, Enzyme-Linked Immunosorbent Assay (ELISA), and Turbidimetric Immunoassay.
  • Based on Application, market is studied across Diagnosis & Disease Progression Monitoring and Research.
  • Based on End-User, market is studied across Diagnostic Laboratories and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of renal disorders among population
      • 5.1.1.2. Growing initiatives to create awareness on renal diseases and renal biomarkers
      • 5.1.1.3. Trend towards developing personalized medicines and targeted therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with renal biomarkers
    • 5.1.3. Opportunities
      • 5.1.3.1. Robust research activities to introduce new renal biomarkers
      • 5.1.3.2. Emerging technological advancements in renal surgeries
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns over failure of biomarkers
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Renal Biomarkers Market, by Marker Type

  • 6.1. Introduction
  • 6.2. Blood Urea Nitrogen
  • 6.3. Creatinine
  • 6.4. Cystatin C
  • 6.5. Neutrophil Gelatinase-Associated Lipocalin

7. Renal Biomarkers Market, by Assay Platform Type

  • 7.1. Introduction
  • 7.2. Enzymatic Assay
  • 7.3. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 7.4. Turbidimetric Immunoassay

8. Renal Biomarkers Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnosis & Disease Progression Monitoring
  • 8.3. Research

9. Renal Biomarkers Market, by End-User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals

10. Americas Renal Biomarkers Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Renal Biomarkers Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Renal Biomarkers Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. BioPorto Diagnostics A/S
  • 7. Cipla Limited
  • 8. Danaher Corporation
  • 9. DiaSorin S.p.A.
  • 10. Eli Lilly and Co
  • 11. Enzo Biochem, Inc.
  • 12. Eurofins Viracor Inc.
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fresenius Kabi AG
  • 15. Novartis AG
  • 16. Novatein Biosciences Inc.
  • 17. PerkinElmer Inc.
  • 18. Randox Laboratories Ltd.
  • 19. Renalytix AI PLC
  • 20. Sanofi-Aventis, LLC.
  • 21. Sekisui Diagnostics, LLC
  • 22. Siemens Healthineers AG
  • 23. SphingoTec GmbH
  • 24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. RENAL BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. RENAL BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RENAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. RENAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. RENAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RENAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RENAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RENAL BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY BLOOD UREA NITROGEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY CREATININE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY CYSTATIN C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ENZYMATIC ASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY TURBIDIMETRIC IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY DIAGNOSIS & DISEASE PROGRESSION MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. RENAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. RENAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023